JP2022515068A5 - - Google Patents

Info

Publication number
JP2022515068A5
JP2022515068A5 JP2021534757A JP2021534757A JP2022515068A5 JP 2022515068 A5 JP2022515068 A5 JP 2022515068A5 JP 2021534757 A JP2021534757 A JP 2021534757A JP 2021534757 A JP2021534757 A JP 2021534757A JP 2022515068 A5 JP2022515068 A5 JP 2022515068A5
Authority
JP
Japan
Prior art keywords
methylcellulose
anhydroglucose
anhydroglucose unit
active ingredient
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534757A
Other languages
English (en)
Japanese (ja)
Other versions
JP7535520B2 (ja
JP2022515068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066712 external-priority patent/WO2020131784A1/en
Publication of JP2022515068A publication Critical patent/JP2022515068A/ja
Publication of JP2022515068A5 publication Critical patent/JP2022515068A5/ja
Application granted granted Critical
Publication of JP7535520B2 publication Critical patent/JP7535520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534757A 2018-12-18 2019-12-17 メチルセルロースを含む徐放性組成物 Active JP7535520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213453 2018-12-18
EP18213453.6 2018-12-18
PCT/US2019/066712 WO2020131784A1 (en) 2018-12-18 2019-12-17 A sustained release composition comprising a methylcellulose

Publications (3)

Publication Number Publication Date
JP2022515068A JP2022515068A (ja) 2022-02-17
JP2022515068A5 true JP2022515068A5 (https=) 2024-04-16
JP7535520B2 JP7535520B2 (ja) 2024-08-16

Family

ID=64744651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534757A Active JP7535520B2 (ja) 2018-12-18 2019-12-17 メチルセルロースを含む徐放性組成物

Country Status (4)

Country Link
US (2) US20220047498A1 (https=)
EP (1) EP3897730A1 (https=)
JP (1) JP7535520B2 (https=)
WO (1) WO2020131784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525831A (ja) 2022-08-02 2025-08-07 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー アルギネートをベースとする放出調節組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2917104A1 (de) 1979-04-27 1980-11-06 Hoechst Ag Verfahren zur viskositaetserniedrigung von celluloseethern durch ozon und seine verwendung
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPS6225101A (ja) 1985-07-24 1987-02-03 Shin Etsu Chem Co Ltd 低重合度セルロ−スエ−テルの製造方法
US4734285A (en) 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US6261218B1 (en) 1998-12-01 2001-07-17 The Dow Chemical Company Process and apparatus for making low molecular weight cellulose ethers
AU3932400A (en) 1999-04-01 2000-10-23 Dow Chemical Company, The Enhanced gel strength methylcellulose
DE10141680B4 (de) 2001-08-25 2004-02-26 Clariant Gmbh Verfahren zur Herstellung niederviskoser Celluloseether durch sauer-oxidativen Abbau von gemahlenen und getrockneten Celluloseethern
EP1761265A2 (en) * 2004-06-28 2007-03-14 ALZA Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
KR20140077975A (ko) 2011-10-19 2014-06-24 다우 글로벌 테크놀로지스 엘엘씨 포만감을 유발하는 방법 및 조성물
BR112014008689A2 (pt) 2011-10-19 2017-04-25 Dow Global Technologies Llc medicamento fluível ou ingerível por colher, alimento, ingrediente alimentício ou suplemento alimentar, método para induzir saciedade ou para reduzir reversivelmente o volume vazio do estômago em um indivíduo e método para reduzir a ingestão calórica em um indivíduo
WO2015009796A1 (en) 2013-07-17 2015-01-22 Dow Global Technologies Llc Composition for application to a mucosa comprising a methylcellulose

Similar Documents

Publication Publication Date Title
KR102072371B1 (ko) 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
WO2015120110A3 (en) Novel pharmaceutical formulations
AR032471A1 (es) Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter
KR20150015209A (ko) 저분자 아세틸화 히알루론산의 제조방법 및 이의 용도
JP2016108327A5 (https=)
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
JP2022105649A5 (https=)
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
JP2022515068A5 (https=)
RU2008147216A (ru) Жидкая лекарственная композиция
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112014032244A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
CN106236761A (zh) 一种包含稀有人参皂苷c‑k的稀有人参皂苷组合物
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
JP2007504194A5 (https=)
JP2022515067A5 (https=)
BRPI0611550A2 (pt) uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto
EA201170528A1 (ru) Производные 1-бутил-2-гидроксиаралкилпиперазина и их применения в качестве лекарственного средства против депрессии
WO2008142140A3 (en) Novel 2,3-diamino-quinazolinone derivatives and their medical use
JP2019511996A5 (https=)
ITFI20130184A1 (it) Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.